Gensight Biologics SA (EUR)
SIGHT
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range3.02 | 3.06
52-Wk Range- | -
Last Close3.04
Mkt Cap (m)99.49
Dividend yield-
ISINFR0013183985
Volume115,554.00
Exchange VenuePAR

Company Profile

Gensight Biologics SA is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and, in the future, of the central nervous system.

Key Information
Price/Earning-
Price/Book8.47
Price/Sales123.26
P/CF-
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % -4,328.29
Net Margin %-4,387.14
Return on Equity-172.45
Debt/Equity0.68

Documents

Prospectus
en 25/05/2016
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.gensight-biologics.com

Financials

Income Statement
EUR201420152016201720182019
Revenue (m)0.000.000.000.000.000.70
Operating Income (m)-6.74-13.66-22.02-23.99-33.05-30.30
Net Income (m)-6.67-13.65-22.08-24.11-33.45-30.71
Basic EPS-0.49-1.00-1.36-1.10-1.37-1.08
Avg. Diluted Shares Outstanding (m)13.6113.6116.2521.9424.4728.38
Balance Sheet
EUR201420152016201720182019
Current Assets (m)14.2735.1158.0760.8135.0827.77
Non Current Assets (m)0.551.201.161.401.904.72
Total Assets (m)14.8236.3159.2362.2136.9832.48
Current Liabilities (m)3.566.292.894.109.6010.51
Total Liabilities (m)------
Total Equity (m)10.5829.3353.3455.0023.8711.75
Cash Flows
EUR201420152016201720182019
Operating Cash Flows (m)-5.52-12.09-19.64-18.78-28.38-28.11
Capital Expenditure (m)-0.19-0.71-0.19-0.24-0.79-0.08
Figures are quoted in EUR unless stated otherwise
-
No change
3.04
Last Price